Sanofi (NYSE:SNY)‘s stock had its “neutral” rating restated by equities researchers at UBS Group in a research note issued to investors on Monday, www.boersen-zeitung.de reports.

Several other brokerages also recently weighed in on SNY. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Morgan Stanley downgraded Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, December 14th. Finally, Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $51.50.

Shares of Sanofi (NYSE SNY) traded up $0.77 during trading hours on Monday, reaching $44.78. The company had a trading volume of 1,659,800 shares, compared to its average volume of 1,292,944. Sanofi has a 1 year low of $39.42 and a 1 year high of $50.65. The company has a market cap of $112,913.13, a P/E ratio of 11.42, a price-to-earnings-growth ratio of 2.58 and a beta of 0.87. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59.

Sanofi (NYSE:SNY) last announced its earnings results on Thursday, November 2nd. The company reported $1.00 earnings per share for the quarter, meeting the consensus estimate of $1.00. Sanofi had a return on equity of 25.19% and a net margin of 25.44%. research analysts predict that Sanofi will post 3.3 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in SNY. BlackRock Inc. lifted its position in shares of Sanofi by 47.6% in the 2nd quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock worth $107,100,000 after acquiring an additional 720,523 shares during the period. Investment Centers of America Inc. bought a new position in shares of Sanofi during the 2nd quarter worth approximately $300,000. Strategic Global Advisors LLC lifted its position in shares of Sanofi by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock worth $414,000 after buying an additional 54 shares during the period. UBS Asset Management Americas Inc. lifted its position in shares of Sanofi by 22.7% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 75,475 shares of the company’s stock worth $3,616,000 after buying an additional 13,959 shares during the period. Finally, FMR LLC lifted its position in shares of Sanofi by 3.0% during the 2nd quarter. FMR LLC now owns 5,374,385 shares of the company’s stock worth $257,487,000 after buying an additional 155,751 shares during the period. Institutional investors own 9.08% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Sanofi (SNY) Stock Rating Reaffirmed by UBS Group” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/15/sanofi-sny-stock-rating-reaffirmed-by-ubs-group.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.